Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PaxMedica, Inc. (PXMD)
OTHER OTC:PXMD
Holding PXMD?
Track your performance easily
PXMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.06 - $10.26
Previous Close$0.12
Volume41.42K
Average Volume (3M)89.65K
Market Cap
$1.28M
Enterprise Value$959.26K
Total Cash (Recent Filing)$324.49K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 13, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.88
Shares Outstanding10,879,170
10 Day Avg. Volume100,324
30 Day Avg. Volume89,652
Standard Deviation0.26
R-Squared0.01
Alpha-0.16
Financial Highlights & Ratios
Price to Book (P/B)-0.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PaxMedica, Inc. News
Ownership Overview
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PXMD FAQ
What was PaxMedica, Inc.’s price range in the past 12 months?
PaxMedica, Inc. lowest stock price was $0.06 and its highest was $10.26 in the past 12 months.
What is PaxMedica, Inc.’s market cap?
Currently, no data Available
When is PaxMedica, Inc.’s upcoming earnings report date?
PaxMedica, Inc.’s upcoming earnings report date is Nov 13, 2024 which is in 3 days.
How were PaxMedica, Inc.’s earnings last quarter?
Currently, no data Available
Is PaxMedica, Inc. overvalued?
According to Wall Street analysts PaxMedica, Inc.’s price is currently Overvalued.
Does PaxMedica, Inc. pay dividends?
PaxMedica, Inc. does not currently pay dividends.
What is PaxMedica, Inc.’s EPS estimate?
PaxMedica, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PaxMedica, Inc. have?
PaxMedica, Inc. has 10,879,170 shares outstanding.
What happened to PaxMedica, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PaxMedica, Inc.?
Currently, no hedge funds are holding shares in PXMD
---
PaxMedica, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PXMD Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-96.36%
12-Months-Change
Fundamentals
Return on Equity
-7716.47%
Trailing 12-Months
Asset Growth
-84.46%
Trailing 12-Months
Company Description
PaxMedica, Inc.
PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.
---
PXMD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering PXMD
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-86.00%
initiated a buy rating 11 months ago
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -86.00% per trade.
---